Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREASURE-CKD tirzepatide study in overweight or obesity with chronic kidney disease
NL-OMON58994Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD), obesity, Overweight and 1 more comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Percent change from baseline in renal sinus fat content. Started May 2023; status: completed.
02
Drugs
03
Conditions
chronic kidney disease (CKD)obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON58994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58994.